Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
Go back to Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing| Quest Diagnostics (NYSE: DGX) | Delayed: 227.90 +18.07 (8.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $209.83 | 52 Week High | $86.85 | |||
| Open | $228.09 | 52 Week Low | $59.66 | |||
| Day High | $237.78 | P/E | 42.92 | |||
| Day Low | $220.00 | EPS | $5.31 | |||
| Volume | 3,758,422 | |||||
